Selected clinical investigations and medications prescribed during the first or any encounter within the same episode of treatment for lactational mastitis in women attending general practice, Australia, 2011 to 2022
| First encounter | Any encounter* | |
| Clinical investigations | ||
| Breast ultrasound | 1 393 (5.6%) | 1 771 (7.1%) |
| Milk culture | 195 (0.8%) | 235 (0.9%) |
| Nipple swab culture | 237 (0.9%) | 283 (1.1%) |
| Breast aspirate | 37 (0.1%) | 64 (0.3%) |
| Blood test | 835 (3.3%) | 962 (3.8%) |
| FBE | 823 (3.3%) | 947 (3.8%) |
| CRP | 278 (1.1%) | 350 (1.4%) |
| ESR | 179 (0.7%) | 212 (0.8%) |
| Medication prescriptions | ||
| Antibiotics | ||
| Oral | 22 523 (90.1%) | 22 739 (90.9%) |
| Di/flucloxacillin | 12 477 (49.9%) | 12 794 (51.2%) |
| Cefalexin | 8 223 (32.9%) | 8 501 (34.0%) |
| Amoxicillin | 754 (3.0%) | 772 (3.1%) |
| Amoxicillin clavulanate | 594 (2.4%) | 664 (2.7%) |
| Clindamycin | 315 (1.3%) | 354 (1.4%) |
| Erythromycin | 289 (1.2%) | 308 (1.2%) |
| Other | 174 (0.7%) | 215 (0.9%) |
| Intravenous | 20 (0.1%) | 32 (0.1%) |
| Topical | 125 (0.5%) | 149 (0.6%) |
| Antifungals | ||
| Oral | 275 (1.1%) | 326 (1.3%) |
| Topical | 303 (1.2%) | 349 (1.4%) |
| Other medications | ||
| Lactation suppressants | 270 (1.1%) | 310 (1.2%) |
| Lactation stimulants | 256 (1.0%) | 295 (1.2%) |
*At any encounter for mastitis, including additional encounters occurring within a 2-week period of a previous mastitis encounter.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FBE, Full blood examination.